What Researchers Did
The researchers looked at 12 diabetic foot ulcers in 11 patients who were offered amputation as a last option, and gave each ulcer an injection of a growth factor medicine into the wound.
What They Found
In this small case series of 11 patients with advanced diabetic foot ulcers, 10 of 12 lesions healed completely after injection of epidermal growth factor (75 µg), and 2 patients had an amputation. The 11 patients (8 males, 3 females) had an average age of 62.2 years. Most had already had revascularization, hyperbaric oxygen therapy (HBOT) and negative pressure wound therapy, along with standard care, and their wounds had not healed. The 10 healed lesions were in 9 of the remaining patients. The authors concluded that the injection can prevent amputations in advanced ischemic cases, but they also noted that supporting evidence in the literature is lacking and that the treatment is costly.
What This Means for Canadian Patients
This study tested the growth factor injection, not HBOT. HBOT was one of the treatments most patients had already received without their wounds healing. The authors suggest the injection should be an option only after vascular evaluation (and intervention when possible), HBOT, negative pressure wound therapy and standard care have proven insufficient. With so few patients and no comparison group, these results do not show what HBOT itself did.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study was small (11 patients), had no comparison group, and the abstract reports no statistical testing, so it cannot show that the injection caused the healing or separate its effect from the earlier treatments.